Previous 10 | Next 10 |
OLUMIANT® Significantly Improved Hair Regrowth to At Least 80% Scalp Coverage as Early as 24 Weeks Across First Completed Phase 3 Studies for Alopecia Areata - Potential first-in-disease treatment for millions of adults worldwide living with alopecia areata (AA) - - Saf...
Syndax Pharmaceuticals and Incyte Announce Global Collaboration to Develop and Commercialize Axatilimab for Chronic Graft-Versus-Host Disease and Other Fibrotic Diseases - Syndax to receive $ 152 million in cash ($117 million upfront plus a $35 million equity investment, with po...
This portfolio strategy uses the quarterly 13F filings to extract 50 consensus stocks from 40 large hedge funds that have more than $3.5 billion Assets Under Management. After the Q2-2021 13F filings, the consensus holdings were updated. 6 stocks were removed and 6 added from the univ...
The following slide deck was published by Incyte Corporation in conjunction with this event. For further details see: Incyte Corporation (INCY) Opzelura (ruxolitinib) cream FDA Approval Presentation - Slideshow
MONTREAL, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, today announced that it has entered into a definitive agreement with Incyte Biosciences International Sàrl, the Swiss-bas...
- Jakafi is approved for treatment of chronic GVHD after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older - Today’s approval marks the fourth FDA-approved indication for Jakafi, which received FDA-approval in 2019 for st...
The stock market got off to a strong start on Wednesday, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) benefited from more positive sentiment on Wall Street. As of 10 a.m. EDT, the Nasdaq was up more than half a percent, continuing to claw back some of the ground it lost in Monday's...
- Opzelura is the first and only topical Janus kinase (JAK) inhibitor approved in the United States - In Phase 3 studies, Opzelura significantly reduced the skin inflammation and itch associated with AD - Investor conference call and webcast scheduled for September 22,...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
News, Short Squeeze, Breakout and More Instantly...
2024-07-12 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 11:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-02 06:15:05 ET BMO Capital analyst issues UNDERPERFORM recommendation for INCY on July 2, 2024 04:26AM ET. The previous analyst recommendation was Market Perform. INCY was trading at $60.87 at issue of the analyst recommendation. The overall analyst consensus : B...